Simcere Pharma of Nanjing acquired China rights to develop three bi-specific immunoncology antibodies from Merus, a Dutch biopharma. The candidates were developed using Merus’ proprietary Biclonics® technology platform. Simcere, which earlier was a company focused on branded generics for China, has expanded through partnerships and internal R&D to develop new drugs. The company has established a four-biosimilar China marketing pact with Amgen and three collaborations with Bristol-Myers Squibb.
Source: China Biotoday
